-
1.发明授权METHOD OF PREPARING POLYMORPHIC PURE FORM A OF BAZEDOXIFENE ACETATE 有权一种用于生产多晶型PURE FORM A OFF醋酸巴多昔芬
公开(公告)号：EP2658843B1
公开(公告)日：2016-11-02
申请号：EP11802097.3
申请日：2011-12-21
申请人： Sandoz AG
IPC分类号： C07D209/12 , C07D403/12 , A61K31/404 , A61K31/55 , A61P19/10 , A61K9/16
CPC分类号： C07D403/12 , A61K9/1617 , A61K31/404 , A61K31/55 , C07D209/12
-
公开(公告)号：EP2977372A1
公开(公告)日：2016-01-27
申请号：EP15181097.5
申请日：2011-06-24
申请人： SANDOZ AG
IPC分类号： C07D277/56 , A61K31/425 , A61P19/06
CPC分类号： C07D277/56
摘要： The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
摘要翻译： 本发明涉及非甾体酮的结晶形式I以及包含结晶形式I作为活性药物成分的药物组合物。 此外，本发明涉及另一种指定为形式II的非诺沙星的多晶型物，还涉及一种新颖的非索非司坦溶剂合物。 本发明还涉及制备结晶形式I，形式II和新戊酸钠的新溶剂化物的方法。
-
公开(公告)号：EP2318396B9
公开(公告)日：2013-05-29
申请号：EP09772368.8
申请日：2009-06-25
申请人： Sandoz AG
IPC分类号： C07D405/14 , A61K31/496 , A61P31/10
CPC分类号： C07D405/06 , C07D405/14
-
公开(公告)号：EP2707368B1
公开(公告)日：2016-02-03
申请号：EP12721484.9
申请日：2012-05-09
申请人： Sandoz AG
发明人： HOTTER, Andreas , PICHLER, Arthur
IPC分类号： C07D473/04 , A61K31/522
CPC分类号： C07D473/06 , A61K31/522 , A61K45/06 , C07D473/04
-
公开(公告)号：EP2897943A1
公开(公告)日：2015-07-29
申请号：EP13762872.3
申请日：2013-09-18
申请人： Sandoz AG
IPC分类号： C07D295/096 , A61K31/495 , A61P25/00
CPC分类号： C07D295/096 , A61K31/495
摘要： The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2[2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2&thetas;±0.2° 2&thetas; (CuKα radiation)) at 5.5°, 14.8°, 16.7° and 20.0° and processes for obtaining the same.
-
6.发明授权
公开(公告)号：EP2318004B1
公开(公告)日：2013-04-10
申请号：EP09757457.8
申请日：2009-05-28
申请人： Sandoz AG
发明人： WIESER, Josef , PICHLER, Arthur , HOTTER, Andreas , GRIESSER, Ulrich , LANGES, Christoph , LASCHOBER, Christian
IPC分类号： A61K31/496 , A61P31/10
CPC分类号： A61K31/496
-
公开(公告)号：EP2318396B1
公开(公告)日：2012-10-24
申请号：EP09772368.8
申请日：2009-06-25
申请人： Sandoz AG
IPC分类号： C07D405/14 , A61K31/496 , A61P31/10
CPC分类号： C07D405/06 , C07D405/14
-
公开(公告)号：EP2318396A1
公开(公告)日：2011-05-11
申请号：EP09772368.8
申请日：2009-06-25
申请人： Sandoz AG
IPC分类号： C07D405/14 , A61K31/496 , A61P31/10
CPC分类号： C07D405/06 , C07D405/14
摘要： The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.
-
9.发明公开HYDROGENSULFATE SALT OF 2-ACETOXY-5-(a-CYCLOPROPYLCARBONYL-2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION 审中-公开2-乙酰氧基-5-（A-环丙基羰基-2-氟苄基）的亚硫酸氢盐-4,5,6,7-四氢[3,2-c]吡啶及其制造
公开(公告)号：EP2285812A1
公开(公告)日：2011-02-23
申请号：EP09734647.2
申请日：2009-04-23
申请人： Sandoz AG
发明人： HOTTER, Andreas , WIESER, Josef , PICHLER, Arthur
IPC分类号： C07D495/04 , A61K31/4365 , A61P7/02
CPC分类号： C07D495/04
摘要： The present invention relates to crystalline form I of Prasugrel hydrogensulfate. A process for the preparation of these salts, pharmaceutical compositions comprising the salts and the use of the salts as a pharmaceutical, in particular as a blood platelet aggregation inhibitor are also described. Seed crystals which can be employed in the above mentioned process as well as a process for their preparation are also disclosed.
-
公开(公告)号：EP2178827A1
公开(公告)日：2010-04-28
申请号：EP08761262.8
申请日：2008-06-20
申请人： Sandoz AG
发明人： WIESER, Josef , PICHLER, Arthur , HOTTER, Andreas
IPC分类号： C07C237/26 , A61K31/65 , A61P31/00
CPC分类号： C07C237/26 , C07C2603/46
摘要： The present invention relates to the new crystalline solid form VI and VIII of tigecycline and processes for the production of form VI and VIII. It further relates to a new method for preparing Form I and Form III in high polymorphic purity.
摘要翻译： 本发明涉及替加环素的新结晶固体形式VI和VIII以及生产VI和VIII型的方法。 它还涉及一种制备高多晶型纯度的I型和III型的新方法。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.018 秒)
